Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 2,750,000 shares, a growth of 24.4% from the March 31st total of 2,210,000 shares. Based on an average trading volume of 996,300 shares, the short-interest ratio is presently 2.8 days. Approximately 2.7% of the company’s shares are short sold.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alliancebernstein L.P. raised its holdings in Regeneron Pharmaceuticals by 13.4% during the fourth quarter. Alliancebernstein L.P. now owns 1,763,344 shares of the biopharmaceutical company’s stock valued at $851,889,000 after buying an additional 208,936 shares in the last quarter. Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $506,839,000. Bank of New York Mellon Corp grew its position in shares of Regeneron Pharmaceuticals by 1.0% in the fourth quarter. Bank of New York Mellon Corp now owns 828,264 shares of the biopharmaceutical company’s stock valued at $400,141,000 after purchasing an additional 8,138 shares during the last quarter. UBS Asset Management Americas Inc. grew its position in Regeneron Pharmaceuticals by 8.7% during the fourth quarter. UBS Asset Management Americas Inc. now owns 643,442 shares of the biopharmaceutical company’s stock worth $310,853,000 after buying an additional 51,243 shares in the last quarter. Finally, Swiss National Bank grew its holdings in shares of Regeneron Pharmaceuticals by 4.6% during the 4th quarter. Swiss National Bank now owns 596,122 shares of the biopharmaceutical company’s stock worth $287,992,000 after purchasing an additional 26,000 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.
Shares of REGN traded down $3.44 during trading hours on Tuesday, hitting $485.18. 745,603 shares of the company were exchanged, compared to its average volume of 977,554. The company has a market capitalization of $51.98 billion, a PE ratio of 17.73, a PEG ratio of 0.82 and a beta of 0.30. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.89 and a quick ratio of 3.12. The firm has a fifty day simple moving average of $482.38 and a 200-day simple moving average of $503.31. Regeneron Pharmaceuticals has a one year low of $441.00 and a one year high of $664.64.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 4th. The biopharmaceutical company reported $9.53 earnings per share for the quarter, topping the consensus estimate of $7.11 by $2.42. The business had revenue of $2.42 billion during the quarter, compared to analyst estimates of $2.40 billion. Regeneron Pharmaceuticals had a return on equity of 28.97% and a net margin of 38.28%. The company’s revenue was up 11.7% compared to the same quarter last year. During the same period last year, the company posted $7.50 EPS. Sell-side analysts expect that Regeneron Pharmaceuticals will post 27.23 EPS for the current year.
Several equities research analysts have recently issued reports on the stock. Robert W. Baird reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 13th. Smith Barney Citigroup raised their price target on shares of Regeneron Pharmaceuticals from $575.00 to $584.00 in a report on Thursday, January 14th. FIX raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $635.00 to $575.00 in a report on Friday, January 8th. BMO Capital Markets raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a report on Monday, January 25th. Finally, Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $525.00 to $477.00 and set an “equal weight” rating for the company in a report on Monday, April 26th. Five investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $644.17.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: What is a bull market?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.